Get the Stockscreener App
1.37
1.43%
-0.03
Ocugen Inc stock is traded at $1.37, with a volume of 2.32M.
It is down -1.43% in the last 24 hours and down -2.13% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.40
Open:
$1.41
24h Volume:
2.32M
Relative Volume:
0.36
Market Cap:
$464.58M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-5.9103
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
+11.29%
1M Performance:
-2.13%
6M Performance:
-2.13%
1Y Performance:
+33.98%
1-Day Range:
$1.36
$1.44
1-Week Range:
$1.25
$1.44
52-Week Range:
$0.98
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.37 | 474.75M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
522.33 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
810.65 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.03 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.12 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
355.03 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen at Canaccord Genuity’s 46th Annual Growth Conference: late-stage push - Investing.com Canada
Research Analysts Issue Forecasts for Ocugen Q3 Earnings - MarketBeat
What is Noble Financial's Forecast for Ocugen Q3 Earnings? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN - MarketBeat
Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Yahoo Finance
Ocugen Inc (OCGN) Stock News Today - TradingKey
State Street Corporation (NYSE: STT) reports 6.3% beneficial stake in Ocugen - Stock Titan
Ocugen Q2 Earnings Call Highlights - Yahoo Finance
Ocugen (NASDAQ:OCGN) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Cleara - GuruFocus
Form 8K Ocugen, Inc For: 6 August By Investing.com - Investing.com South Africa
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. 2026: Revenue $1.49M, EPS ($0.07) — 10-Q Summary - TradingView
Ocugen (NASDAQ: OCGN) raises $112.5M via converts as losses hit $44.1M - Stock Titan
Ocugen, Inc. Announces Management Changes - marketscreener.com
Earnings call transcript: Ocugen posts Q2 2026 revenue beat as loss widens - Investing.com
OCGN: FDA cleared phase III for OCU410; cash runway extended to 2028 after $130M financing - TradingView
Ocugen Provides Business Update with Second Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Ocugen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ocugen reports $1.49M Q2 revenue, $0.07 loss per share and $100.4M cash as of June 30, 2026 - TradingView
Ocugen: Q2 Earnings Snapshot - marketscreener.com
Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing - quiverquant.com
Press Release: Ocugen Provides Business Update With Second Quarter 2026 Financial Results - Moomoo
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Ocugen Inc (2H51.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
FDA grants OCU410 regenerative medicine advanced therapy designation for geographic atrophy - AllSci
Ocugen to Present Modifier Gene Therapy Platform at Upcoming August 2026 Investor Conferences - quiverquant.com
A one-time treatment for geographic atrophy gains FDA RMAT status - Stock Titan
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OCGN|Ocugen Inc|Price:1.262|Chg%:+0.051 - TradingKey
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc (OCGN) Balance Sheet - TradingKey
Ocugen Inc (OCGN) Cash Flow - TradingKey
Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
Ocugen Inc (OCGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
OCGN|Ocugen Inc|Price:1.210|Chg%:-0.060 - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
0.31%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):